Den her er ogsaa interessant ifm Novo Nordisk, fordi bluebird og Novo har et haemofili-forskningssamarbejde. Bluebird bio stiger 10% i pre market.
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-priority-review-biologics-license
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-and-novo-nordisk-enter-research-agreement-develop
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-priority-review-biologics-license
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-and-novo-nordisk-enter-research-agreement-develop
